Brief: Paratek Pharmaceuticals - Q1 Revenue Rose 107% To $16.4 Mln
17/05/2021 12:43
May 17 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* Q1 REVENUE ESTIMATE $28.7 MILLION -- REFINITIV IBES DATA
* QTRLY LOSS PER SHARE $0.39
* BARDA HAS INITIATED FIRST PROCUREMENT OF NUZYRA VALUED AT
ABOUT
$38 MILLION IN Q2 OF 2021
* NUZYRA EXPANSION INTO PRIMARY CARE SETTING UNDERWAY
Source text for Eikon: ID:nGNX6XcMNV
Further company coverage: PRTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million